Anaconda Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has closed €20 million in new investment. The funding will be used for clinical studies, regulatory submissions in international markets, further product development and manufacturing scale-up.

Asabys Partners led the round from its fund, Sabadell Asabys, with participation from existing investors Ysios Capital, Omega Funds and Innogest, as well as Sabadell Venture Capital.

Anaconda Biomed is a CataloniaBio & HealthTech member. In 2018, the company founded by Ofir Arad and Marc Ribó, won the Biosuccess Award.

More information

You may also be interested in:

• Anaconda announces first-in-human study of next-generation thrombectomy system
• Anaconda Biomed appoints new CMO and Manufacturing Director

Photo: Sylvain Sachot and Josep Lluís Sanfeliu (Asabys) and François Salmon and Ofir Arad (Anaconda) - © Anaconda Biomed